Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 5Breast 5Gynecologic 3Thoracic 2Head & Neck 2Genitourinary 2Gastrointestinal 2CNS 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Endocrine 1Dermatologic 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Pheochromocytoma 1Paraganglioma 1Ovarian Neoplasms 1Mesothelioma 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 9Specimen Handling 7tislelizumab 6Pemetrexed 6Cisplatin 6Carboplatin 6fludarabine 5atezolizumab 5Interviews as Topic 5Injections 5Cyclophosphamide 5Bevacizumab 5Platinum 4Fluorouracil 4Educational Status 4Biopsy 4Standard of Care 3Practice Guidelines as Topic 3Nivolumab 3Methods 3Magnetic Resonance Spectroscopy 3Early Intervention, Educational 3Cetuximab 31,2-diaminocyclohexaneplatinum II citrate 3sintilimab 2sacituzumab govitecan 2fludarabine phosphate 2X-Rays 2Trastuzumab 2Radiotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fluorodeoxyglucose F18 × Other solid neoplasm × 30 days × Clear all
NCT06503146 2026-05-19

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
320 enrolled
CNSEndocrineGastrointestinalGenitourinaryGynecologicOther solid neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Carcinoma, Hepatocellular, Mesothelioma, Ovarian Neoplasms, Paraganglioma, Pheochromocytoma, Sarcoma, Stomach Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡